Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 3Leukemia, Promyelocytic, Acute 3Neuroblastoma 1Li-Fraumeni Syndrome 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Temozolomide 16Irinotecan 13Cyclophosphamide 11dinutuximab 9naxitamab 7Vincristine 7Carboplatin 6sargramostim 5Melphalan 5Granulocyte-Macrophage Colony-Stimulating Factor 5Etoposide 5fludarabine 4Topotecan 4Thiotepa 4Eflornithine 4Doxorubicin 4Cisplatin 4etoposide phosphate 3Zoledronic Acid 3Specimen Handling 3Isotretinoin 3Granulocyte Colony-Stimulating Factor 3saponin QA-21V1 2lutetium Lu 177 dotatate 2aldesleukin 2Vorinostat 2Stem Cell Transplantation 2Radiation 2Platinum 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neuroblastoma × Arsenic Trioxide × Clear all
NCT06933394 2025-04-18

Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Recruiting
92 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡